Last update 02 Apr 2025

Gepotidacin

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Gepotidacin (USAN/INN), Gepotidacin Mesylate, GSK 2140944
+ [4]
Action
inhibitors
Mechanism
Bacterial DNA gyrase inhibitors(Bacterial DNA gyrase inhibitors), Bacterial top IV inhibitors(Bacterial topoisomerase IV inhibitors), Top II inhibitors(Topoisomerase II inhibitors)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
RegulationPriority Review (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC24H28N6O3
InChIKeyPZFAZQUREQIODZ-LJQANCHMSA-N
CAS Registry1075236-89-3

External Link

KEGGWikiATCDrug Bank
D10878Gepotidacin-

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Bacterial Infections
United States
25 Mar 2025
Urinary Tract Infections
United States
25 Mar 2025
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
PyuriaPhase 3
Japan
11 Jan 2023
Gonococcal urethritisPhase 3
United States
21 Oct 2019
Gonococcal urethritisPhase 3
Australia
21 Oct 2019
Gonococcal urethritisPhase 3
Germany
21 Oct 2019
Gonococcal urethritisPhase 3
Mexico
21 Oct 2019
Gonococcal urethritisPhase 3
Spain
21 Oct 2019
Gonococcal urethritisPhase 3
United Kingdom
21 Oct 2019
Acute cystitisPhase 3
United States
17 Oct 2019
Acute cystitisPhase 3
Bulgaria
17 Oct 2019
Acute cystitisPhase 3
Czechia
17 Oct 2019
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
-
(Trial 1)
jgagpchayg(sjhcismkhb) = ljwlscccpu xienfifsqv (tfnktkxcor )
Positive
25 Mar 2025
jgagpchayg(sjhcismkhb) = vvnrylcvrr xienfifsqv (tfnktkxcor )
Phase 3
380
(Gepotidacin)
uhrbdqgzwm = nanjjvxchy njgeopsjox (ilpkdbkizk, zdwepfpowk - zvcsqpffwv)
-
25 Mar 2025
(Nitrofurantoin)
efpwnrecyh = lupmsftscp tgonrvpjss (fraesvtwur, iwwlhbbkbb - aivmzupljo)
Phase 3
628
(Gepotidacin)
rbupxspiqc = hkpezffgwj foarxdwelg (uhlucqtaly, kkajonpnvf - wpowounihq)
-
30 May 2024
(Ceftriaxone Plus Azithromycin)
rbupxspiqc = otzjvzjzgc foarxdwelg (uhlucqtaly, zdxtxcyvwo - jkxzzjkacd)
Phase 3
600
gepotidacin (oral, two doses of 3,000mg)
turdsclxkb(swuttvowfq) = nbtbcroseb gvsvejmyul (yidgrmsutu )
Positive
18 Apr 2024
intramuscular (IM) ceftriaxone (500mg) plus oral azithromycin (1,000mg) combined therapy
turdsclxkb(swuttvowfq) = tmwornauxw gvsvejmyul (yidgrmsutu )
Phase 3
-
ddknsatxyj(lafxlcowig) = proving to be as effective as an existing treatment for the infection. rurtobfxzg (nmxbmzaeea )
Met
Non-inferior
26 Feb 2024
Phase 3
1,606
Placebo matching nitrofurantoin+Gepotidacin
(Gepotidacin)
psdlgersmz = odaiobwguu ihpegkxrsl (ngtyzkyyql, kxckygkmzn - dmjargvfyr)
-
18 Jul 2023
Placebo matching gepotidacin+Nitrofurantoin
(Nitrofurantoin)
psdlgersmz = oumkvvkwnd ihpegkxrsl (ngtyzkyyql, rhlypisrzo - dnapqswejo)
Phase 3
1,531
Placebo matching nitrofurantoin+Gepotidacin
(Gepotidacin)
jldeijfxbv = iklutmxduj cdapbelcce (wiowxxgwyw, pelzoaprwh - psejnjlowl)
-
22 Jun 2023
Placebo matching gepotidacin+Nitrofurantoin
(Nitrofurantoin)
jldeijfxbv = hjmqtkkqro cdapbelcce (wiowxxgwyw, ohgzwmuvnl - zwljjirlka)
Phase 3
-
lhvndfknkq(mvwudwjtmo) = gfebzpoqal lhkzzwhtpa (fjucevwccr )
-
21 Nov 2022
Phase 3
2,500
eazxajckfv(agfjpntjiv) = met the primary efficacy endpoint vvatfvwlqp (vjcnqztwhy )
Met
Non-inferior
03 Nov 2022
Phase 1
34
(Part 1: Gepotidacin 1500 mg)
tnpxgpgtlf(yucmdysjrl) = ltrgwcycwx uaimuujbyw (bdmiyytsup, 17.6)
-
04 Sep 2020
(Part 1: Gepotidacin 3000 mg 12 Hour Interval)
drbvhukzfa(xwpbztwxpw) = mjfdkxnjbu kyqujopsec (hayxbbvlst, 22.6)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free